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Les substances polyfluoroalkyle et perfluoroalkyle (PFAS) constituent une classe de 
produits chimiques de synthèse communément utilisés dans les articles ménagers et de 
consommation. Ils sont trouvés dans les batteries de cuisine en Téflon ™ car ils dissuadent 
l'eau, la graisse et l'huile; les composés fluorochimiques se sont révélés utiles pour divers 
procédés de fabrication. Le sous-groupe important est constitué d’acides perfluoroalkyliques 
(PFAAs), qui comprennent le sulfonate de perfluorooctane (PFOS) et l’acide 
perfluorooctanoïque (PFOA). Chez les rongeurs et les singes, il a été démontré qu'ils 
augmentaient le poids du foie et provoquaient une accumulation de graisse dans le foie ou 
une stéatose du foie. 1–4
PFAAs are the first generation of PFASs synthesized by companies. Little is known 
about other PFAS and newer shorter carbon chain length compounds that are being used to 
replace the original PFAS compounds since they are supposed to be better for humans and 
the environment. However, not enough testing has been done to prove this, and so we 
wanted to test these new PFAS replacements to see if they are as toxic or even more toxic 
than the original PFAS compound. Some of these compounds have been named precursor 
PFAS, because they degrade and become the old PFAAs. 1 The PFASs that we have chosen 
to test are perfluorooctane sulfonamide (FOSA), n-methylperfluoro-1-octanesulfonamide 
(MetFOSA), n-ethylperfluoro-1-octanesulfonamide (EtFOSA), 1 H, 1 H, 2 H, 2 H-
perfluorooctane sulfonic acid (6:2 FTS), perfluoro-n-pentanoic acid (PFPeA (C5)), 
perfluoro-n-tridecanoic acid (PFTrDA (C13)), and perfluoro-n-tetradecanoic acid (PFTeDA 
(C14)). 5
Based on our preliminary data and other research done, which shows that some
PFAAs induce lipid deposition in hepatocytes based on chain length and functional
groups, we decided that the next experiment should test PFAS precursors. Therefore, we
hypothesized that the newer emerging PFASs may also have a capacity to induce lipid
accumulation than legacy PFAAs. Since the experiment will be about testing the novel
endpoint with emerging PFASs that are replacing widely used PFAAs, there will be three
different types of procedures being used, hepatocyte treatments, nile red staining, and
gene expression measurements.
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v Attempt #1: Preliminary data had no significance in any of the precursors
nor the P/O. The fold change values were too low.
v Attempt #2: Using the spectrometer instrument showed that the numbers
were still too low and that there was not much significance other than
FOSA and MetFOSA precursors at the 0.25 µM concentrations.
v Image J results from Attempt #2: Shows that the P/O fold changes were not
as high as 1.5 or more to be significant, so the results were not as
anticipated, but it did show that FOSA and MetFOSA precursors had
significant fold changes at the 25 µM concentrations.
Les données étant toutes similaires, il a été suggéré que l’application du
traitement pourrait être problématique, mais pas le traitement lui-même. Dans
les deux tentatives et l'analyse d'image, il a été connu pour augmenter
l'accumulation de lipides. De plus, une des raisons pour lesquelles le nombre de
cellules était si bas était due à une erreur humaine, telle que frapper le fond des
puits tout en passant l'aspirateur; en conséquence, tuant certaines des cellules
par accident.
Our next step will be to redo this experiment but with the treatment applied 
differently, while using spectrometer instrument analysis and quantification of 
nile red/DAPI staining on Image J.  Then, we will conduct gene expression 
analysis on plate 2 using the same plate design, except P/O will be replaced with 
rosiglitazone (ROSI) and next to it in the 4 wells, we will add  clofibrate (CLO).
FIGURE 3: Nile Red 
Mean Grey Value and 
DAPI Nuclei Stain 
Images from EVOS 
Microscope.
These  are images of Nile 
Red (pink/red) and DAPI            
(Blue) Nuclei Stains
overlapping, which 
show that the FOSA, 
EtFOSA, 6:2 FTS, C5, 
and C13 precursors have 
more Nile Red staining 
than DAPI staining. This 
is the opposite for 
MetFOSA precursor, P/O 
positive Control, and 
DMSO. Scale=100µm. 
40x magnification.
FIGURE 1: Attempt #1 Preliminary Plate 1 Data of Nile Red Staining.
Neither the precursors nor the P/O fold change values were high enough to be
significant , therefore the experiment was done again using the same plate design
and procedures. Calculations were done using an ANOVA followed by
Fisher’s LSD test. All values are means ± SEM; N = 3-4. “*” indicates
p<0.05.
FIGURE 2: Attempt #2 Plate 1 Data of Nile Red Staining from Spectrometer
Instrument Data.
Based on the Fold Change calculations, it showed that the P/O positive control
was too low. Since the positive control has to be significant, meaning 1.5-2 to
show an increase in lipid accumulation, the wells were looked at underneath the
microscope showing that the bottom of the wells were hit too many times. So for
a more accurate cell count, images were taken to quantify the fluorescence
intensity.
FIGURE 4: Quantification of Image J staining from Attempt #2 of Plate 1.
Human hepatocytes were treated with PFAS precursors for 48 hours and
stained with nile red and DAPI. Staining for the 25 µM treatment groups was
quantified by Image J for each of the wells. Only the 25 µM concentrations
were imaged not including C14, in order to save time. FOSA and MetFOSA
increased the hepatic lipid staining.
Hepatocyte plating and culture: Used a Cryostax pool of human hepatocytes from 5 
donors from Xenotech LLC (Lenexa, KS). Then, cyropreserved hepatocytes were thawed 
and cultured  on a 96-well plate following Xenotech protocols for cell suspension and 
counting the dead (blue) cells and viable (alive) cell number (yellow) using a 
hemacytometer, as well as Xenotech certified reagents such as OptiCulture Media 
solution and OptiMatrix.
Hepatocyte Cell Treatments:
Nile-red Staining: After 72h of treatments, including lipid inducing positive control (1:2 
palmitate and oleate, P/O, at 0.25 µM), cells were fixed with 10% formalin for 10 min and 
washed with PBS. Cells were then stained with Nile Red (3.1 µM for 10-15 min) and DAPI 
(300 nM for 1-5 min) and washed with PBS. Nile red fluorescence was measured (excitation 
485nm/emission 535nm) was normalized to DAPI fluorescence (excitation 358nm/emission 
461nm). Cells were imaged using EVOS cell imaging system.
Quantification of staining by Image J: Only the 25 µM concentrations were imaged but 
not including C14, in order to save time. A scale of 100 µm with a 40x magnification was 
used for imaging to count DAPI’s nuclei and find the mean gray values of the Nile Red 
Images to quantify the fluorescence intensity.
Statistical Analysis from Spectrometer Instrument: Calculations were done using one-
way ANOVA followed by Fisher’s LSD test.  All values in heat maps are average fold 
change values compared to DMSO controls (included on each 96-well plate), Bar graphs are 
means ± SEM; N = 3-4 per group
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Treatment with:
24 hrs after plating, cells were treated with PFASs at various 
concentrations (25 µM, 2.5 µM, and 0.25 µM) or 0.1% DMSO vehicle. 
Treatments were continued for 48 hrs or 72h. Every 24 hrs, media was 
removed and replaced by fresh media containing treatments.
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